Wednesday November 25 2009 | Biotechnology feed | All feeds
|
|
Karen SorrentoEpiVax, Inc.
Download detailed PDF Members: EpiVax has developed comprehensive analytical capabilities in the field of computational immunology. We are dedicated to applying our tools to reengineering therapeutic proteins and to designing new vaccines. We leverage our tools and expertise adding value to our clients’research and development efforts while we apply them to our ownpipeline of therapeutic proteins and vaccine candidates. We have extensive immunology and microbiology laboratory capabilities including the most sophisticated MHC binding assays on the market. Because our assays utilize highly purified recombinant soluble class I and class II MHC molecules rather than whole cells or lysates, we can achieve the greatest level of specificity and sensitivity.EpiVax knows the scientific, financial, and regulatory challenges faced by today’s pharmaceutical industry and applies this know-how at every step from design to execution to IND.
This page has been viewed 238 times since April 2007, the link to the organisation's website has been followed 44 times Search for more companies in Providence Search for more companies in Rhode Island This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Karen SorrentoEpiVax, Inc. | |||||||||||||||||||||||||||||||||||||||||
|